Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?

Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?

Cisplatin-based chemotherapy has been the standard of care in metastatic urothelial cancer (mUC) for more than two decades. However, many patients with comorbidities cannot receive cisplatin or its alternative, carboplatin. ‘Cisplatin-ineligible’ and ‘platinum-ineligible’ patients lacked effective t...

Full description

Bibliographic Details
Main Authors:	Mohammad Jad Moussa, Matthew T. Campbell, Omar Alhalabi
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Biomedicines
Subjects:	metastatic urothelial cancer cisplatin-based chemotherapy platinum-based chemotherapy cisplatin ineligible platinum ineligible enfortumab vedotin
Online Access:	https://www.mdpi.com/2227-9059/12/3/519

Similar Items

Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis
by: Huitao Wang, et al.
Published: (2019-12-01)

The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy
by: Jiwei Huang, et al.
Published: (2022-12-01)

Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study
by: Ruopeng Su, et al.
Published: (2023-05-01)

A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada
by: Feras A. Moria, et al.
Published: (2024-01-01)

How I manage frontline transplant-ineligible multiple myeloma
by: Daniele Derudas, et al.
Published: (2020-09-01)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
by: Bunpei Isoda, et al.
Published: (2023-06-01)

Synthesis and Pharmacological Evaluation of Modified Adenosines Joined to Mono-Functional Platinum Moieties
by: Stefano D'Errico, et al.
Published: (2014-07-01)

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective
by: Yunlin Jiang, et al.
Published: (2023-09-01)

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents
by: Angelico D. Aputen, et al.
Published: (2023-04-01)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
by: Shafique MA, et al.
Published: (2023-07-01)

Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions
by: Yuki Endo, et al.
Published: (2024-01-01)

Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved Outcomes
by: Giles M, et al.
Published: (2023-07-01)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
by: Moussa M, et al.
Published: (2021-02-01)

Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma
by: Fubin Zhu, et al.
Published: (2023-09-01)

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
by: Nobuaki Matsubara, et al.
Published: (2023-02-01)

Insights on Lipomatosis after Platinum-Based Chemotherapy Use in Pediatric Oncology: A Case Report
by: Estera Boeriu, et al.
Published: (2022-11-01)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
by: Jordi Rubió-Casadevall, et al.
Published: (2023-08-01)

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
by: Jiazheng Yu, et al.
Published: (2023-07-01)

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
by: Wenjiao Tang, et al.
Published: (2024-01-01)

Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma
by: Tetsushi Murakami, et al.
Published: (2021-09-01)

Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
by: Marco Audisio, et al.
Published: (2022-05-01)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
by: Jain RK, et al.
Published: (2020-09-01)

Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China
by: Wei Guo, et al.
Published: (2022-06-01)

Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted
by: Reem Ali, et al.
Published: (2022-06-01)

Urothelial carcinoma management in elderly or unfit patients
by: Joaquim Bellmunt, et al.
Published: (2016-03-01)

DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?
by: Nuno Tiago Tavares, et al.
Published: (2022-06-01)

Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
by: Akinori Minato, et al.
Published: (2024-02-01)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
by: Takashi Kawahara, et al.
Published: (2023-08-01)

Socioepidemiological screening of serologically ineligible blood donors due to Chagas disease for the definition of inconclusive cases
by: Márcia M Ferreira-Silva, et al.
Published: (2010-09-01)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
by: Furubayashi N, et al.
Published: (2020-10-01)

Cisplatin Induced Nephrotoxicity
by: Seyed Seifollah Beladi Mousavi, et al.
Published: (2014-02-01)

Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity
by: Mostafa Abdelsalam, et al.
Published: (2018-09-01)

Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity
by: Angelico D. Aputen, et al.
Published: (2024-02-01)

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort
by: Stefanie Zschäbitz, et al.
Published: (2023-07-01)

Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy
by: David Sanford, et al.
Published: (2022-09-01)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
by: Zhang SS, et al.
Published: (2022-04-01)

Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
by: Hira Mian, et al.
Published: (2023-02-01)

Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis
by: Zhiru Li, et al.
Published: (2022-06-01)

Desquamative extravasation reaction secondary to enfortumab vedotin
by: Akshay N. Pulavarty, MD, MPH, et al.
Published: (2024-04-01)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
by: Thibodeau A, et al.
Published: (2021-10-01)